PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study

Management and treatment of terminal metastatic castration-resistant prostate cancer (mCRPC) remains heavily debated. We sought to investigate the efficacy of programmed cell death 1 (PD-1) inhibitor plus anlotinib as a potential solution for terminal mCRPC and further evaluate the association of ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Xin-Xing, Dong, Yan-Hao, Zhu, Han-Jing, Fei, Xiao-Chen, Gong, Yi-Ming, Xia, Bin-Bin, Wu, Fan, Wang, Jia-Yi, Liu, Jia-Zhou, Fan, Lian-Cheng, Wang, Yan-Qing, Dong, Liang, Zhu, Yin-Jie, Pan, Jia-Hua, Dong, Bai-Jun, Xue, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Invited Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069691/
https://www.ncbi.nlm.nih.gov/pubmed/36537376
http://dx.doi.org/10.4103/aja2022102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069691/
https://www.ncbi.nlm.nih.gov/pubmed/36537376
http://dx.doi.org/10.4103/aja2022102

Ejemplares similares